Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.

ABSTRACT: Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study of postmenopausal women with low BMD, a second course of romosozumab following a period off treatment or on denosumab increased or maintained BMD, respectively, and was well tolerated, providing insight into treatment sequence options.

Introduction

In patients with high fracture risk, therapies that stimulate bone formation provide rapid BMD gains; currently available agents, parathyroid hormone receptor agonists, are limited to a 2-year lifetime exposure and generally used for a single treatment course. However, for long-term osteoporosis management, a second treatment course may be appropriate. Romosozumab, a therapy with the dual effect of increasing bone formation and decreasing bo

SUBMITTER: Kendler DL 

PROVIDER: S-EPMC6877701 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature